4.4 Article

Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

Emmanuel Bachy et al.

Summary: This study is a randomized phase III study comparing Ro-CHOP with CHOP in previously untreated adult PTCL patients. The study results showed that the addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency of grade >= 3 treatment-emergent adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Hematology

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Norbert Schmitz et al.

Summary: A comparison between autologous stem cell transplantation (auto-SCT) and allogeneic stem cell transplantation (allo-SCT) in younger patients with peripheral T-cell non-Hodgkin lymphoma showed improved outcomes in terms of long-term event-free survival and overall survival with allo-SCT, but also higher transplant-related mortality.
Article Pathology

Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases

Chunni Chen et al.

Summary: Monomorphic epitheliotropic T-cell lymphoma (MEITL) is an aggressive non-Hodgkin lymphoma with high fatality rate. This study aimed to explore clinicopathological and molecular genetic features of MEITL in Chinese population. The study found that clinicopathological features in Chinese MEITL cases were consistent with those in previous western studies, but a special case with pleomorphic cells was discovered. Co-occurrence of JAK-STAT pathway-related gene mutations and Chr9q amplification is a molecular feature of MEITL.

DIAGNOSTIC PATHOLOGY (2021)

Article Oncology

Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents

Manman Deng et al.

Summary: The study indicates that DLBCL/HGBCL patients with MYC/TP53 dual abnormalities exhibit poor clinical outcomes and high-grade morphology, suggesting the need for additional targeted therapies.

MOLECULAR CANCER RESEARCH (2021)

Article Medicine, Research & Experimental

STAT5B(N642H) is a driver mutation for T cell neoplasia

Ha Thi Thanh Pham et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Article Hematology

Double-hit chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain

Elise Chapiro et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Article Immunology

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2

Andrea B. Moffitt et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2017)

Article Oncology

The Genetic Basis of Hepatosplenic T-cell Lymphoma

Matthew McKinney et al.

CANCER DISCOVERY (2017)

Article Multidisciplinary Sciences

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

Can Kucuk et al.

NATURE COMMUNICATIONS (2015)

Article Pathology

Profile of CD103 Expression in T-cell Neoplasms

Elizabeth A. Morgan et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)

Letter Medicine, General & Internal

TET2 and DNMT3A Mutations in Human T-Cell Lymphoma

Lucile Couronne et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Review Biochemistry & Molecular Biology

Redefining tumour suppressor genes: exceptions to the two-hit hypothesis

AJW Paige

CELLULAR AND MOLECULAR LIFE SCIENCES (2003)